Siglec Programs

About OncoC4

OncoC4 is a private, clinical-stage biotech focused on novel immuno-oncology and neurodegenerative disease therapeutics. Its core strategy involves targeting both established (CTLA-4, PD-1) and emerging (CD24, Siglec) immune checkpoints with a pipeline of monoclonal antibodies, bispecifics, and antibody-drug conjugates. The company has established a key partnership with BioNTech for its lead CTLA-4 asset and operates with a lean, global team. OncoC4 is positioned in the competitive but high-potential fields of next-generation cancer immunotherapy and neuro-immunology.

Therapeutic Areas